Meet the Nimble-Fingered Interface of the Future

Microsoft's Kinect, a 3-D camera and software for gaming, has made a big impact since its launch in 2010. Eight million devices were sold in the product's.....

Electronic Implant Dissolves in the Body

Researchers at the University of Illinois at Urbana-Champaign, Tufts University, and ......

Sorting Chip May Lead to Cell Phone-Sized Medical Labs

The device uses two beams of acoustic -- or sound -- waves to act as acoustic tweezers and sort a continuous flow of cells on a ....

TDK sees hard drive breakthrough in areal density

Perpendicular magnetic recording was an idea that languished for many years, says a TDK technology backgrounder, because the ....

Engineers invent new device that could increase Internet

The device uses the force generated by light to flop a mechanical switch of light on and off at a very high speed........


Showing posts with label LIFE. Show all posts
Showing posts with label LIFE. Show all posts

DNA logic gates herald injectable computers

DNA-based logic gates that could carry out calculations inside the body have been constructed for the first time. The work brings the prospect of injectable biocomputers programmed to target diseases as they arise.
"The biocomputer would sense biomarkers and immediately react by releasing counter-agents for the disease," says Itamar Willner of the Hebrew University of Jerusalem, Israel, who led the work.


The new logic gates are formed from short strands of DNA and their complementary strands, which in conjunction with some simple molecular machinery mimic their electronic equivalent. Two strands act as the input: each represents a 1 when present or a 0 when absent. The response to their presence or absence represents the output, which can also be a 1 or 0.

Take the "exclusive OR" or XOR logic gate. It produces an output when either of the two inputs is present but not when both are present or both are absent. To put the DNA version to the test, Willner and his team added molecules to both the complementary strands that caused them to fluoresce when each was present in isolation, representing a logical 1 as the output. But when both were present, the complementary strands combined and quenched the fluorescence, representing a 0 output.

Simultaneous calculations

One of DNA computing's advantages is that it allows calculations to be carried out in parallel, if different types of logic gates are represented by different ingredients. The team tested this process by tossing the XOR ingredients into a test tube, along with those for two other gates, to produce the first few steps involved in binary addition and subtraction.

The team was also able to create logic gates that calculate in sequence. The trick here is to make the output from the first gate a new DNA string that can be used as the input for a second gate and so on. Such "cascading gates" allow for more complex calculations: the entire set of steps required for addition and subtraction, for example, or to deliver a multi-step drug treatment.

Previous DNA-based computers tended to slow down at each step as the DNA strands were used only once, and so became depleted with time. One significant advance claimed by Willner and his team is that their DNA strands reform after each step, allowing long sequences of calculations to be carried out easily for the first time.

Even a single logic gate could have useful medical applications, Willner says. His group built and tested a gate designed to reduce the activity of the blood-clotting enzyme thrombin, which can lead to brain damage following a head injury. The gate acts as a switch that is triggered by the presence of thrombin. Part of the gate consists of a DNA strand connected to a molecule that binds to thrombin. If thrombin is present, this molecule is released, otherwise it stays bound and inert. Such a smart drug could be injected into the bloodstream in advance and would only switch on when needed (Nature Nanotechnology, DOI: 10.1038/nnano.2010.88).

Another problem with earlier DNA computers is that they use enzymes to manipulate the DNA, and so function only in certain chemical environments that cannot easily be reproduced inside the body. Willner's team use DNA-like molecules to do this job.

"Being enzyme-free, it has potential in future diagnostic and medical applications," says Benny Gil of the Weizmann Institute of Science in Rehovot, Israel. He is impressed with the new gate system but recognises that it will take years of research and development to bring "smart drugs" to medicine.

by Kate McAlpine 

Stem cells turn into seek-and-destroy cancer missiles

GENETICALLY modified stem cells are to be injected into the brains of cancer patients, where they will convert an inactive cancer drug into a potent and targeted tumour-killing agent.


Stem cells are strongly attracted towards cancer cells, so it is hoped that as well as homing in on the main tumour, they will also be drawn to secondary growths, or metastases. This will enable higher doses of drug to be delivered to cancer cells while minimising the risk of side effects in the rest of the body.

A team led by Karen Aboody at the City of Hope Beckman Research Institute in Duarte, California, used neural stem cells originally derived from human fetuses which had been genetically engineered to produce cytosine deaminase. This is an enzyme that converts a drug called 5-fluorocytosine (5-FC) into an active chemotherapy drug, 5-fluorouracil (5-FU), but only in the immediate vicinity of the stem cell.

The team then injected the modified stem cells into the brains of mice with glioma, an aggressive form of brain cancer. The animals were subsequently given 5-FC. Treated mice saw a 70 per cent reduction in tumour mass compared with untreated animals. "In effect, we're allowing a much higher dose of chemo to be localised to the tumour site," says Aboody, who presented the results in May at an international brain tumour conference in Travemünde, Germany.

The US Food and Drug Administration has granted Aboody approval to carry out a safety trial of the therapy in up to 20 patients with recurrent glioma, for whom life expectancy is just three to six months. The stem cells will be injected into the tumour cavity following surgery to reduce its mass, and then given four days to home in on any remaining cancer cells. Patients will then be treated with daily 5-FC for one week.

Tiny colonies of glioma cells often spread deep into healthy brain tissue, but Aboody hopes that the new treatment will be able to zero in on single tumour cells, meaning it could destroy even the smallest metastases.
Evan Snyder at the Sanford-Burnham Medical Research Institute in La Jolla, California, who first proposed the use of stem cells to fight cancer, suggests the same cues that make a tumour invade normal tissue also make a stem cell migrate to that site. "I believe the same concept will work for metastatic cancers that go outside the brain, and for other kinds of cancers," he says.

Unlike clinical trials that use neural stem cells to repair damage caused by stroke, the stem cells used by Aboody have not been seen to differentiate, and stop dividing after 48 hours. This should reduce concerns about the potential for stem cells to trigger cancers in their own right.

by Linda Geddes